Charles River Laboratories International, Inc.’s stock price takes a hit, falling to $165.35 with a 4.91% dip

Charles River Laboratories International, Inc. (CRL)

165.35 USD -8.53 (-4.91%) Volume: 1.54M

Charles River Laboratories International, Inc.’s stock price currently stands at 165.35 USD, experiencing a decrease of -4.91% in today’s trading session with a trading volume of 1.54M. Year-to-date, the stock has seen a percentage change of -10.43%, indicating a challenging market performance for CRL.

Latest developments on Charles River Laboratories International, Inc.

Despite underperforming its competitors on Thursday, Charles River Laboratories International Inc. saw its stock hold rating maintained by Jefferies with a price target of $169. This news comes as FairJourney Biologics recently acquired Charles River’s South San Francisco facility, potentially impacting the company’s future growth prospects and stock price movements. Investors will be closely monitoring how these recent developments will shape the trajectory of Charles River Laboratories in the coming days.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Charles River Laboratories has a mixed long-term outlook. While the company scores well in terms of Momentum, indicating strong performance in the market, it lags behind in areas such as Dividend and Growth. This suggests that while Charles River Laboratories may be experiencing short-term success, there may be challenges in terms of long-term growth and stability.

Charles River Laboratories International, Inc. provides research tools and support services for drug discovery and development. The company’s focus on providing animal research models for pharmaceutical and biotechnology companies, hospitals, and academic institutions positions it as a key player in the industry. However, with lower scores in areas such as Dividend and Growth, investors may want to consider the overall outlook carefully before making long-term investment decisions.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

Before it’s here, it’s on Smartkarma